Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$1.69M$1.69M+17.1% vs Q3 2016 Net Income$14.32M$14.32M−54.1% vs Q3 2016 EPS Diluted$0.12$0.12−60.0% vs Q3 2016 Gross Profit$1,636,000+13.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,681,000N/M Free Cash Flowderived-$8,137,000— Margins · derivedGross margin96.9%−3.1 pt vs Q3 2016
Operating margin-563.6%+99.5 pt vs Q3 2016
Net margin848.4%
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end